184 related articles for article (PubMed ID: 33078260)
1. Promising potential of [
Guzik P; Siwowska K; Fang HY; Cohrs S; Bernhardt P; Schibli R; Müller C
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):984-994. PubMed ID: 33078260
[TBL] [Abstract][Full Text] [Related]
2. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
3. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.
Müller C; Reber J; Haller S; Dorrer H; Bernhardt P; Zhernosekov K; Türler A; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):476-85. PubMed ID: 24100768
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy.
Guzik P; Benešová M; Ratz M; Monné Rodríguez JM; Deberle LM; Schibli R; Müller C
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):972-983. PubMed ID: 33063250
[TBL] [Abstract][Full Text] [Related]
5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
6. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
7. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
8. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
[TBL] [Abstract][Full Text] [Related]
9. 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy.
Reber J; Haller S; Leamon CP; Müller C
Mol Cancer Ther; 2013 Nov; 12(11):2436-45. PubMed ID: 24030631
[TBL] [Abstract][Full Text] [Related]
10. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.
Aranda-Lara L; Ferro-Flores G; Azorín-Vega E; Ramírez FM; Jiménez-Mancilla N; Ocampo-García B; Santos-Cuevas C; Isaac-Olivé K
Appl Radiat Isot; 2016 Jan; 107():214-219. PubMed ID: 26545016
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
13. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
14. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of
Luna-Gutiérrez M; Cruz-Nova P; Jiménez-Mancilla N; Oros-Pantoja R; Lara-Almazán N; Santos-Cuevas C; Azorín-Vega E; Ocampo-García B; Ferro-Flores G
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569758
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of
Siwowska K; Guzik P; Domnanich KA; Monné Rodríguez JM; Bernhardt P; Ponsard B; Hasler R; Borgna F; Schibli R; Köster U; van der Meulen NP; Müller C
Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31434360
[TBL] [Abstract][Full Text] [Related]
17. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
J Nucl Med; 2016 Jun; 57(6):936-42. PubMed ID: 26848176
[TBL] [Abstract][Full Text] [Related]
18. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
Busslinger SD; Becker AE; Vaccarin C; Deberle LM; Renz ML; Groehn V; Schibli R; Müller C
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686538
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
